Catalyst Pharmaceuticals, Inc. (CPRX)
Largest Insider Buys in Sector
CPRX Stock Price History Chart
CPRX Stock Performance
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular …
Insider Activity of Catalyst Pharmaceuticals, Inc.
Over the last 12 months, insiders at Catalyst Pharmaceuticals, Inc. have bought $0 and sold $11.94M worth of Catalyst Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Catalyst Pharmaceuticals, Inc. have bought $130,960 and sold $12.26M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $89,100 was made by MCENANY PATRICK J (President and CEO) on 2020‑09‑30.
List of Insider Buy and Sell Transactions, Catalyst Pharmaceuticals, Inc.
| 2024-08-21 | Sale | director | 15,000 0.0124% | $20.10 | $301,455 | -0.73% | ||
| 2024-08-20 | Sale | Chief Op. & Scientific Officer | 150,000 0.1243% | $20.35 | $3.05M | -1.64% | ||
| 2024-08-09 | Sale | Chief Med. & Reg. Officer | 100,000 0.0826% | $18.04 | $1.8M | +9.96% | ||
| 2024-08-09 | Sale | Chief Commercial Officer | 36,058 0.0304% | $18.42 | $664,310 | +9.96% | ||
| 2024-06-07 | Sale | Chief Commercial Officer | 7,541 0.0066% | $16.07 | $121,184 | +27.37% | ||
| 2024-06-05 | Sale | Chief Med. & Reg. Officer | 80,000 0.0671% | $16.16 | $1.29M | +21.96% | ||
| 2024-06-04 | Sale | President and CEO | 17,323 0.0146% | $15.97 | $276,735 | +23.94% | ||
| 2024-06-03 | Sale | director | 5,333 0.0045% | $16.30 | $86,949 | +22.68% | ||
| 2024-04-08 | Sale | director | 25,000 0.0214% | $15.68 | $392,000 | +7.87% | ||
| 2024-03-27 | Sale | Chief Compliance/Legal Officer | 25,000 0.0214% | $16.44 | $411,000 | +1.51% | ||
| 2023-12-15 | Sale | director | 14,000 0.0132% | $14.39 | $201,420 | +12.02% | ||
| 2023-12-12 | Sale | director | 50,000 0.0468% | $13.32 | $666,250 | +20.23% | ||
| 2023-12-11 | Sale | VP, Treasurer and CFO | 60,000 0.0561% | $13.76 | $825,780 | +15.98% | ||
| 2023-12-08 | Sale | VP, Treasurer and CFO | 40,000 0.0378% | $14.28 | $571,000 | +12.76% | ||
| 2023-12-06 | Sale | Chief Med. & Reg. Officer | 50,000 0.0469% | $14.02 | $701,000 | +14.43% | ||
| 2023-12-05 | Sale | Chief Op. & Scientific Officer | 40,000 0.0377% | $14.24 | $569,600 | +12.95% | ||
| 2023-05-15 | Sale | President and CEO | 26,151 0.0249% | $13.23 | $345,978 | +5.78% | ||
| 2023-04-05 | Sale | director | 30,000 0.0283% | $16.83 | $504,900 | -18.07% | ||
| 2023-03-29 | Sale | VP, Treasurer and CFO | 50,000 0.0473% | $16.70 | $835,100 | -17.05% | ||
| 2023-03-29 | Sale | Chief Commercial Officer | 40,000 0.0378% | $16.70 | $667,810 | -17.05% |
Insider Historical Profitability
| Miller Steve | Chief Op. & Scientific Officer | 675124 0.5688% | $22.73 | 3 | 8 | +36.11% |
| Tierney David S | director | 348874 0.2939% | $22.73 | 3 | 7 | +8.21% |
| GRANDE ALICIA | VP, Treasurer and CFO | 50557 0.0426% | $22.73 | 6 | 14 | +54.75% |
| BIOMARIN PHARMACEUTICAL INC | 10 percent owner | 6666667 5.617% | $22.73 | 1 | 0 | |
| MCENANY PATRICK J | President and CEO | 3945436 3.3242% | $22.73 | 36 | 8 | +56.01% |
Institutional Investor Ownership
| BlackRock | $282.66M | 15.01 | 17.73M | +12.07% | +$30.45M | 0.01 | |
| Deerfield Management | $145.55M | 7.73 | 9.13M | +2.72% | +$3.86M | 0.36 | |
| State Street | $129.96M | 6.9 | 8.15M | +20.12% | +$21.77M | 0.01 | |
| The Vanguard Group | $127.21M | 6.76 | 7.98M | +12.08% | +$13.71M | <0.01 | |
| Dimensional Fund Advisors | $43.64M | 2.32 | 2.74M | +5.22% | +$2.17M | 0.01 |